Qualitative instant diagnostic technique for maxillary and mandibular malignant growth by patient's blood serum and oral fluid biomarkers

FIELD: medicine.

SUBSTANCE: venous blood and oral fluid are sampled from a patient in any sequence. An oral fluid biomarker is presented by carcino-embryonal antigen (CEA). A blood plasma biomarker is presented by neuron-specific enolase. If the oral fluid CEA is found in an amount of 196.8-318.4 ng/ml, while an amount of plasma neuron-specific enolase is 26.3-34.2 ng/ml, sarcoma of jaw bones is diagnosed. If the oral fluid CEA is found in an amount of 1228.2-1762 ng/ml with an amount of plasma neuron-specific enolase being 38.67-57.67 ng/ml, squamous cell carcinoma of jaw bones is diagnosed. The findings are used to predict a therapeutic approach to the patient.

EFFECT: invention provides high-sensitive and accurate differential diagnostic technique of maxillary and mandibular malignant new growths on the day of visit to a doctor.

2 cl, 6 ex

 

The invention relates to medicine, namely to the way rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of the patient, and can be used for rapid qualitative detection of cancer of the organs of the mouth in the dental, cancer and surgical treatment options.

A known method for the diagnosis of malignant neoplasms of the oral cavity organs on the content of biomarkers in plasma and oral fluid of the patient, including studies of plasma venous blood and oral fluid of the patient while performing oral fluid intake of the patient in the morning, before or no sooner than 2 hours after ingestion by the patient and after rinsing the oral cavity of the patient boiled water at room temperature, centrifuging the oral fluid of a patient at 1500 rpm for 5 minutes, diluted oral fluid saline solution in a ratio of 1:10 and re-centrifugation at 1500 rpm for 5 minutes the accommodation ready for study material oral fluid of a patient in a cuvette and the implementation of standard immunoelectrophoresis analysis based on monoclonal antibodies, the execution of the saphenous vein harvesting the heat of the blood of a patient, obtaining blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes, the routine immunoelectrophoretic analysis of blood plasma, followed by analysis of the research results (see kochurova EV Value of tumor markers in salivary fluid with squamous cell cancer of the oral cavity organs. Dissertation CMN, Moscow, 2008, p.28).

However, the known method when its use has the following disadvantages:

has poor accuracy differential diagnosis of malignant neoplasm of bones of the upper and lower jaws of the patient on the same day,

- lacks sensitivity differential diagnosis

the failure probability of detection process of malignant neoplasm of bones of the upper and lower jaws of the patient, as in the early stages of the disease, and later,

- the complexity of the preparation of the patient in a certain time frame for collection of diagnostic material.

The objective of the invention is to provide a method rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of the patient.

The technical result is to the achieving significant improvement in the accuracy of differential diagnosis of malignant neoplasm of bones of the upper and lower jaws of the patient on the same day, achieving high sensitivity differential diagnosis, achieving a high probability of detection process of malignant neoplasm of bones of the upper and lower jaws of the patient, as in the early stages of the disease, and later, as well as a significant simplification of the preparation of the patient in a certain time frame for collection of diagnostic material.

The technical result is achieved in that a method is proposed for rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of the patient, including studies of plasma venous blood and oral fluid of the patient while performing oral fluid intake of the patient in the morning, before or no sooner than 2 hours after ingestion by the patient and after rinsing the oral cavity of the patient boiled water at room temperature, centrifuging the oral fluid of a patient at 1500 rpm for 5 minutes, diluted oral fluid saline solution in a ratio of 1:10 and repeated centrifugation at 1500 rpm for 5 minutes, the accommodation ready for study material oral fluid of a patient in a cuvette and the implementation of standard immunoelectrophoresis analysis based on monoclonal antibodies, which execute sampling of venous blood of the patient, obtaining blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes, the routine immunoelectrophoretic analysis of blood plasma, followed by analysis of the research results, while venous blood and oral fluid in any sequence taken from a patient for research malignancies, as biomarker in oral fluid opt cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA), and as a biomarker in the blood plasma of a patient chooses neurospecific enolase / neuron-specific enolase, when the content in the oral fluid of the patient REA/CEA in the number 196,8-318,4 ng/ml and the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 26,3 by 34.2 u/ml, diagnose sarcoma of the jaw of the patient, when the content in the oral fluid of the patient CEA/CEA in the number 1228,2-1762 ng/ml and the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 38,67-57,67 u/ml, diagnosed with squamous cell carcinoma of the jaw of the patient, then the results of the determination of biomarkers in plasma and oral fluid of the patient predict the tactics of treatment of the patient. If necessary short-term storage of venous blood of the patient PE the ed analysis it number add 5 ml in a test tube with 1 ml of 0.14 M sodium citrate, centrifuged at 1500 rpm for 5 minutes, take the blood plasma in the form above sedimentary fluid, placed in a test tube "Eppendorf" and immediately frozen in liquid nitrogen at minus 190°C.

The method is as follows. Oral fluid and venous blood in any sequence taken from the patient for rapid qualitative detection of malignant tumors. Perform oral fluid intake of the patient in the morning, before or no sooner than 2 hours after taking them food and after rinsing the mouth by the patient boiled water at room temperature. Oral fluid of the patient centrifuged at 1500 rpm for 5 minutes, diluted oral fluid is a saline solution in a ratio of 1:10 and re-centrifugation at 1500 rpm for 5 minutes. Ready to research material oral fluid a patient is placed in a cuvette and perform standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche-Moscow" (Switzerland) based on monoclonal antibodies.

Perform the sampling of venous blood of the patient, get the blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes. If necessary short-term storage of venous blood of the patient before made the eating of analysis in an amount of 5 ml added to a test tube with 1 ml of 0.14 M sodium citrate, centrifuged at 1500 rpm for 5 minutes, take the blood plasma in the form above sedimentary fluid, placed in a test tube "Eppendorf" and immediately frozen in liquid nitrogen at minus 190°C.

Perform standard immunoelectronmicroscopy analysis of blood plasma.

As a biomarker for rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the amount of biomarkers in oral fluid opt cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) and determine its quantitative content in the oral fluid of the patient. For the quantitative content of the biomarker in oral fluid cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) group clinical supervision take level 77,6-of 142.8 ng/ml.

Determine if the content in the oral fluid of the patient's cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) 196,8-318,4 ng/ml, diagnose sarcoma of the jaw of the patient.

Determine if the content in the oral fluid of the patient's cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) in the amount of 1228,2-1762 ng/ml, diagnosed with squamous cell carcinoma of the jaw of the patient.

As biomarker in rapid qualitative detection of malignant neoplasm of upper and lower jaws on the quantities of the content of biomarkers in plasma choose neurospecific enolase / neuron-specific enolase and determine its quantitative content in the blood plasma of the patient. For the quantitative content of the biomarker in the blood plasma of the patient neurospecific enolase / neuron-specific enolase group clinical supervision take 4.6-9.0 ng/ml

Determine if the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 34,67-57.67 ng/ml, diagnosed with squamous cell carcinoma of the jaw of the patient.

Determine if the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 26,3 by 34.2 ng/ml, diagnose sarcoma of the jaw of the patient.

Then the results of the determination of biomarkers in plasma and oral fluid of the patient predict the tactics of treatment of the patient.

While in progress or after surgical intervention with preoperative combined, including chemo-radiotherapy treatment of the patient additionally carry out control and determination of biomarkers in plasma and oral fluid of the patient, the results of which are judged on the effectiveness of the selected treatment of the patient.

Among the significant characteristics of the proposed method is rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of the patient, distinctive and are:

- perform sampling of venous blood and oral fluid, in any order patient for rapid qualitative studies of malignant neoplasms,

- selected as a biomarker in oral fluid cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA), and as a biomarker in the blood plasma of the patient neurospecific enolase / neuron-specific enolase,

- diagnosis when the content in the oral fluid of the patient CEA/CEA in the number 196,8-318,4 ng/ml and the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 26,3 by 34.2 u/ml sarcoma of the jaw of the patient,

- diagnosis when the content in the oral fluid of the patient CEA/CEA in the number 1228,2-1762 ng/ml and the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 38,67-57,67 u/ml squamous cell cancer of the jaw of the patient,

- prediction on the results of the determination of biomarkers in plasma and oral fluid of the patient treatment plan of the patient,

- if necessary, short-term storage of venous blood of the patient before performing the analysis in the amount of 5 ml is added to the test tube with 1 ml of 0.14 M sodium citrate, centrifuged at 1500 rpm for 5 minutes to draw the blood plasma in the form above sedimentary fluid, accommodation in vitro "Eppendorf" is immediately freeze in liquid nitrogen at minus 190°C.

Experimental studies of the proposed method is rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of a patient in a clinical setting showed its high efficiency. The way rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of the patient during its use ensures the achievement of a significant improvement in the accuracy of differential diagnosis of malignant neoplasm of bones of the upper and lower jaws of the patient on the day of treatment, achieving high sensitivity differential diagnosis, enables to achieve a high probability of detection process of malignant neoplasm of bones of the upper and lower jaws of the patient, as in the early stages of the disease, and later, as well as provides a significant simplification of the preparation of the patient in a certain time frame for collection of diagnostic material.

Implementation of the proposed method is rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid PA the rate is illustrated by the following clinical examples.

Example 1. Patient C., 55 years old, was admitted to the Department with a presumptive diagnosis of "malignant neoplasm of the upper jaw to the right."

Oral fluid and venous blood in any sequence taken from the patient for rapid qualitative research malignancies. Performed oral fluid intake of the patient in the morning before taking them food and after rinsing the mouth by the patient boiled water at room temperature. Oral fluid the patient was centrifuged at 1500 rpm for 5 minutes, diluted with saline in a ratio of 1:10 and conducted repeated centrifugation at 1500 rpm for 5 minutes. Performed the sampling of venous blood of the patient and received the blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes. Ready to research material oral fluid and blood plasma of a patient placed in a separate cell and performed standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche-Moscow" (Switzerland) based on monoclonal antibodies.

As a biomarker for rapid qualitative detection of malignant tumors of the upper jaw to the right by the number of content biomarkers in oral fluid chose cancer-embryonic anti-Christ. EN/carcino-embryonal antigen (CEA/CEA) and determined its quantitative content in the oral fluid of the patient.

As a biomarker for rapid qualitative detection of malignant tumors of the upper jaw to the right by the number of content biomarkers in plasma chose neurospecific enolase / neuron-specific enolase and determined its quantitative content in the blood plasma of the patient.

As a result of the analysis has determined the content in the oral fluid of the patient's cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) in the number 1762 ng/ml, and set the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 57,67 ng/ml On the basis of the obtained results was diagnosed with squamous cell carcinoma of the upper jaw on the right. Clinical diagnosis is also confirmed by morphological verification biopsy of the tumor and/or lymph node if necessary. In connection with the data obtained, the patient was assigned to combined treatment: preoperative radiation therapy to the primary tumor site and the way regional metastasis, and then surgical excision of the tumor with subsequent grafting of the defect.

Example 2. Patient U., 72 years old, was admitted to the Department with a presumptive diagnosis of "malignant neoplasm of lower jaw to the right."

Oral fluid and venous blood in any sequence taken from the patient for quality is th Express-diagnostics of malignant neoplasms. Performed oral fluid intake of the patient in the morning before taking them food and after rinsing the mouth by the patient boiled water at room temperature. Oral fluid the patient was centrifuged at 1500 rpm for 5 minutes, diluted with saline in a ratio of 1:10 and conducted repeated centrifugation at 1500 rpm for 5 minutes. Performed the sampling of venous blood of the patient and received the blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes. Ready to research material oral fluid and blood plasma of a patient placed in a separate cell and performed standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche-Moscow" (Switzerland) based on monoclonal antibodies.

As a biomarker for rapid qualitative detection of malignant tumors of the mandible to the right by the number of content biomarkers in oral fluid chose cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) and determined its quantitative content in the oral fluid of the patient.

As a biomarker for rapid qualitative detection of malignant tumors of the mandible to the right by the number of content biomarkers in plasma chose neurospecific is enolase / neuron-specific enolase and determined its quantitative content in the blood plasma of the patient.

As a result of the analysis has determined the content in the oral fluid of the patient's cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) in the amount of 1582,2 ng/ml, and set the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 38,67 ng/ml On the basis of the obtained results was diagnosed with squamous cell carcinoma of the upper jaw on the right. Clinical diagnosis is also confirmed by morphological verification biopsy of the tumor and/or lymph node if necessary. In connection with the data obtained, the patient was assigned to combined treatment: preoperative radiation therapy to the primary tumor site and the way regional metastasis, and then surgical excision of the tumor with subsequent grafting of the defect.

Example 3. Patient Z., 44 years old, was admitted to the Department with a presumptive diagnosis of "malignant neoplasm of lower jaw to the left".

Oral fluid and venous blood in any sequence taken from the patient for rapid qualitative detection of malignant tumors. Performed oral fluid intake of the patient in the morning before taking them food and after rinsing the mouth by the patient boiled water at room temperature. Oral fluid the patient was centrifuged at 1500 rpm for 5 minutes, R is bavili saline solution in a ratio of 1:10 and conducted repeated centrifugation at 1500 rpm for 5 minutes. Performed the sampling of venous blood of the patient and received the blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes. Due to advanced age of the patient have any need for short-term storage of his venous blood, so before you analyze it in an amount of 5 ml was added into a test tube with 1 ml of 0.14 M sodium citrate, centrifuged at 1500 rpm for 5 minutes, took the blood plasma in the form of supernatant was placed in a test tube "Eppendorf" and immediately frozen in liquid nitrogen at minus 190°C. Subsequently prepared for research material oral fluid and blood plasma of a patient placed in a separate cell and performed standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche Moscow (Switzerland) based on monoclonal antibodies.

As a biomarker for rapid qualitative detection of malignant tumors of the mandible to the left by the number of content biomarkers in oral fluid chose cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) and determined its quantitative content in the oral fluid of the patient.

As a biomarker for rapid qualitative detection of malignant tumors of the mandible to the left by the number of the receiving biomarkers in plasma chose neurospecific enolase / neuron-specific enolase and determined its quantitative content in the blood plasma of the patient.

As a result of the analysis has determined the content in the oral fluid of the patient's cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) in the amount of 1228,2 ng/ml, and set the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number 46,9 ng/ml at 99,9% diagnostic sensitivity. On the basis of the obtained results was diagnosed with squamous cell carcinoma of the mandible on the left. Clinical diagnosis is also confirmed by morphological verification biopsy of the tumor and/or lymph node if necessary. In connection with the data obtained, the patient was assigned to combined treatment: preoperative radiation therapy to the primary tumor site and the way regional metastasis, and then surgical excision of the tumor with subsequent grafting of the defect.

Example 4. Patient E., 28 years old, was admitted to the Department with a presumptive diagnosis of "malignant neoplasm of the upper jaw to the right."

Oral fluid and venous blood in any sequence taken from the patient for rapid qualitative research malignancies. Performed oral fluid intake of the patient in the morning no earlier than 2 hours after receiving her food and after rinsing the mouth by the patient boiled water at room temperature. P is the starting fluid the patient was centrifuged at 1500 rpm for 5 minutes, diluted saline solution in a ratio of 1:10 and conducted repeated centrifugation at 1500 rpm for 5 minutes. Performed the sampling of venous blood of the patient and received the blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes. Ready to research material oral fluid and blood plasma of the patient was placed in a separate cell and performed standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche-Moscow" (Switzerland) based on monoclonal antibodies.

As a biomarker for rapid qualitative detection of malignant tumors of the upper jaw to the right by the number of content biomarkers in oral fluid chose cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) and determined its quantitative content in the oral fluid of the patient.

As a biomarker for rapid qualitative detection of malignant tumors of the upper jaw to the right by the number of content biomarkers in plasma chose neurospecific enolase / neuron-specific enolase and determined its quantitative content in the blood plasma of the patient.

As a result of the analysis has determined the content in the oral fluid of the patient cancer cancer-embryonic antigen/carcino-emryonal antigen (CEA/CEA) in the amount of 302,7 ng/ml, as well as installing content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number of 34.2 ng/ml On the basis of the obtained results was diagnosed with sarcoma of the upper jaw on the right. Clinical diagnosis is also confirmed by morphological verification biopsy of the tumor and/or lymph node if necessary. In connection with the data obtained, the patient was scheduled for surgical excision of the tumor with subsequent chemioterapia.

Example 5. Patient L., 52 years old, was admitted to the Department with a presumptive diagnosis of "malignant neoplasm of the upper jaw to the left".

Oral fluid and venous blood in any sequence taken from the patient for rapid qualitative research malignancies. Performed oral fluid intake of the patient in the morning no earlier than 2 hours after receiving her food and after rinsing the mouth by the patient boiled water at room temperature. Oral fluid the patient was centrifuged at 1500 rpm for 5 minutes, diluted with saline in a ratio of 1:10 and conducted repeated centrifugation at 1500 rpm for 5 minutes. Performed the sampling of venous blood of the patient and received the blood plasma in the supernatant after centrifugation of venous blood pazienti 1500 rpm for 5 minutes. Ready to research material oral fluid and blood plasma of the patient was placed in a separate cell and performed standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche-Moscow" (Switzerland) based on monoclonal antibodies.

As a biomarker for rapid qualitative detection of malignant tumors of the upper jaw to the left by the number of content biomarkers in oral fluid chose cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) and determined its quantitative content in the oral fluid of the patient.

As a biomarker for rapid qualitative detection of malignant tumors of the upper jaw to the left by the number of content biomarkers in plasma chose neurospecific enolase / neuron-specific enolase and determined its quantitative content in the blood plasma of the patient.

As a result of the analysis has determined the content in the oral fluid of the patient cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) in the amount of 318,4 ng/ml, and set the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase to 26.3 ng/ml On the basis of the obtained results was diagnosed with sarcoma of the upper jaw on the right. Clinical diagnosis is also confirmed by morphological verification biopsy is the material of the tumor and/or lymph node if necessary. In connection with the data obtained, the patient was scheduled for surgical excision of the tumor with subsequent chemioterapia.

Example 6. Patient I., 48 years old, was admitted to the Department with a presumptive diagnosis of "malignant neoplasm of lower jaw to the right."

Oral fluid and venous blood in any sequence taken from the patient for rapid qualitative research malignancies. Performed oral fluid intake of the patient in the morning before taking them food and after rinsing the mouth by the patient boiled water at room temperature. Oral fluid the patient was centrifuged at 1500 rpm for 5 minutes, diluted with saline in a ratio of 1:10 and conducted repeated centrifugation at 1500 rpm for 5 minutes. Performed the sampling of venous blood of the patient and received the blood plasma in the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes. Ready to research material oral fluid and blood plasma of a patient placed in a separate cell and performed standard immunoelectronmicroscopy analysis apparatus Elecsys 2010 company Roche-Moscow" (Switzerland) based on monoclonal antibodies.

As a biomarker for rapid qualitative detection of malignant newly formed who I lower jaw to the right by the number of content biomarkers in oral fluid chose cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) and determined its quantitative content in the oral fluid of the patient.

As a biomarker for rapid qualitative detection of malignant tumors of the mandible to the right by the number of content biomarkers in plasma chose neurospecific enolase / neuron-specific enolase and determined its quantitative content in the blood plasma of the patient.

As a result of the analysis has determined the content in the oral fluid of the patient cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA) 196,8 ng/ml, and set the content in the blood plasma of the patient neurospecific enolase / neuron-specific enolase in the number of 30.4 ng/ml at 99,9% diagnostic sensitivity. On the basis of the obtained results was diagnosed with sarcoma of the upper jaw on the right. Clinical diagnosis is also confirmed by morphological verification biopsy of the tumor and/or lymph node if necessary. In connection with the data obtained, the patient was scheduled for surgical excision of the tumor with subsequent chemioterapia.

Established clinical diagnosis was later confirmed by the results of morphological verification previously taken from the patient's biopsy material from the lesion.

Established clinical diagnosis was later confirmed by the results of morphological verification pre is taken from a patient biopsy material from the lesion.

By using the proposed method qualitative rapid diagnosis of malignant tumors of the jaw on the content of biomarkers in plasma and oral fluid of a patient during execution or after surgical intervention with preoperative combined, including chemoradiation, patients were additionally carried out the control content determination of biomarkers in plasma and oral fluid of patients whose results were judged on the effectiveness of selected patients.

1. The way rapid qualitative detection of malignant neoplasm of bones of the upper and lower jaws on the content of biomarkers in plasma and oral fluid of the patient, including studies of plasma venous blood and oral fluid of the patient, thus the performance of non-invasive oral fluid intake of the patient in the morning, before or no sooner than 2 hours after ingestion by the patient and after rinsing the oral cavity of the patient boiled water at room temperature, centrifuging the oral fluid of a patient at 1500 rpm for 5 minutes, diluted oral fluid saline solution in a ratio of 1:10 and re-centrifugation at 1500 rpm min for 5 minutes, the accommodation ready for study material is and the oral fluid of a patient in a cuvette and the implementation of standard immunoelectrophoresis analysis based on monoclonal antibodies, perform intake blood plasma of the patient as the supernatant after centrifugation of venous blood of the patient at 1500 rpm for 5 minutes and perform standard immunoelectrophoretic analysis of blood plasma with subsequent analysis of the results of research, characterized in that the venous blood and oral fluid in any sequence taken from a patient for research malignancies, as biomarker in oral fluid opt cancer-embryonic antigen/carcino-embryonal antigen (CEA/CEA), and as a biomarker in the blood plasma of a patient chooses neurospecific enolase/neuron-specific enolase, when the content in the oral fluid patient CEA/CEA in the number 196,8-318,4 ng/ml and the content in the blood plasma of the patient neurospecific enolase/neuron-specific enolase in the number 26,3 by 34.2 u/ml, diagnose sarcoma of the jaw of the patient, when the content in the oral fluid of the patient CEA/CEA in the number 1228,2-1762 ng/ml and the content in the blood plasma of the patient neurospecific enolase/neuron-specific enolase in the number 38,67-57,67 u/ml, diagnosed with squamous cell carcinoma of the jaw of the patient, then the results of the determination of biomarkers in plasma and oral fluid of the patient forecast tactics of treatment of the patient.

2. The method according to claim 1, characterized in that when it is Timoti short-term storage of venous blood of the patient before performing the analysis in the amount of 5 ml added to a test tube with 1 ml of 0,14M citrate, centrifuged at 1500 rpm for 5 minutes, take the blood plasma in the form of the supernatant liquid, placed in a test tube "Eppendorf" and immediately frozen in liquid nitrogen at minus 190°C.



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and deals with a method of determining in an individual's sample of a protein of neutrophilic origin, gelatinase-associated lipocalin (NGAL), for determination of acute kidney injury in the individual, where the predominating amount of monomer and/or heterodimer forms of NGAL protein, in comparison with the dimer form of NGAL protein, shows that NGAL protein originates from the individual's kidneys and that the individual has acute kidney injury, whereas equal or predominating amount of the dimer form of NGAL protein, in comparison with the monomer or heterodimer form of NGAL protein shows that NGAL protein originates from the individual's neutrophils and that the said individual does not have acute kidney injury; a set for determination of relative amounts of monomer, dimer or heterodimer forms of NGAL; application of the device in the said method.

EFFECT: group of inventions ensures more accurate diagnosis and therefore contributes to better directed treatment.

17 cl, 2 ex, 10 dwg, 1 tbl

FIELD: biotechnology.

SUBSTANCE: invention is a method of determining the nonspecific resistance of pathogenic microorganisms to antibiotics and the fact of the presence of bacterial biofilms on the basis of measurement of catalytic activity of phosphodiesterases cleaving the cyclic diguanosine monophosphate, with a threshold sensitivity of 50 pg/ml, comprising: 1) isolating the target-phosphodiesterase from lysed bacterial cells; 2) binding of phosphodiesterase with biotin-conjugated antibodies specific for non-catalytic domains of phosphodiesterase; 3) affinity purification of complexes formed by target-phosphodiesterase and biotin-conjugated antibody using paramagnetic particles containing neutravidin or its analogs that bind biotin; 4) interacting of the complexes of phosphodiesterase/biotin-conjugated antibody, immobilised on paramagnetic particles with complexes containing a-di-GMP in the form of G-quadruplex systems with intercalate dye, which is accompanied by decrease in the intensity while destruction of complexes of intercalate dye with c-di-GMP; 5) measurement of decrease of fluorescence upon hydrolysis with c-di-GMP and destruction of complex of c-di-GMP with intercalate dye, followed by quantitative estimation of the phosphodiesterase activity based on calibration curves made using known amounts of the recombinant enzyme of phosphodiesterase identical to the test target; 6) identification of increased level of phosphodiesterase activity detected by the test antibiotic-resistant bacterial strains capable of biofilm formation, as compared with the level of phosphodiesterase activity that can be detected for the control strains of bacteria of the same species not having the antibiotic resistance and the ability to form biofilms.

EFFECT: method enables to determine the nonspecific resistance of pathogenic microorganisms to antibiotics and to establish the fact of the presence of bacterial biofilms.

4 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.

EFFECT: application of the claimed invention makes it possible to increase accuracy of detecting VEGF isoforms, which must not include isoform VEGF110 and must obligatory include isoform VEGF121.

25 cl, 3 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention represents an immunoassay reagent which contains an agent binding to an analyte in a diluent, and glycosaminoglycan in an amount sufficient to decrease non-specific binding in an analyte sample. In the presented immunoassay reagent, the analyte is troponin I binding to the analyte; the agent is a biotin-modified anti-troponin I antibody, and glycosaminoglycan is chondroitin sulphate. Also, the invention provides a composition containing the troponin I binding agent, and chondroitin sulphate in an amount sufficient to decrease non-specific binding in the troponin I sample. What is also provided is a method of detecting the analyte in the sample wherein non-specific binding is decreased by the use of glycosaminoglycan.

EFFECT: method improvement.

5 ex, 5 dwg

FIELD: medicine.

SUBSTANCE: in the method for assessing action of biologically active substances on the antigen-antibody interaction based on sampling whole blood, stabilising it by an anticoagulant, adding a biologically active substance to the whole blood samples of the groups O(I)-AB(IV), incubating for 3-5 minutes, introducing standard monoclonal anti-A and anti-B antibodies, and 3-5 minutes later, rating the agglutination intensity relevant to the blood group.

EFFECT: improved assessment accuracy.

3 tbl

FIELD: medicine.

SUBSTANCE: flow cytofluorimetry is used to examine peripheral blood for the content of CB34+CB45+hemopoietic precursors on 1-3 pot-injury day, but not earlier than in 8 hours. If the content is lower than 3×106/l, an unfavourable clinical outcome is predicted, while the content 3×106/l and more shows a favourable clinical outcome of a moderate and severe craniocerebral injury.

EFFECT: using the method enables higher accuracy of the early prediction of clinical outcomes in the patients with the craniocerebral injury and the prescription of the adequate differentiated therapy.

3 ex

FIELD: medicine.

SUBSTANCE: what is described is a hybrid cultured cell strain of the animals Mus museums Sp2/0Ag14-SpBcG/APC-15/A3 that is a produced of a monoclonal antibody specific to human protein C (to hPROC). The strain is deposited in the Russian Collection of Vertebrata Cell Culture of the Institute of Cytology of the Russian Academy of Sciences, No. 733(D). What is described is a monoclonal antibody prepared of the strain, specific to hPROC and showing the conformational properties. It binds hPROC in the presence of calcium ions and does not bind it in the presence of chelating agents. What is presented is an immunosorbent on the basis of said antibody.

EFFECT: applicability of the strain for preparing the MCA to hPROC, and producing on its basis an immune-affine sorbent for hPROC purification and concentration.

3 cl, 2 dwg, 3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: blood serum is examined for the content of acuity antibodies M and G to Herpesviridae family viruses, namely herpex simplex type 1 and 2 IgM; cytomegalovirus IgM; cytomegalovirus immediate-early protein IgG and IgM, Epstein-Barr virus core protein IgM, and Epstein-Barr virus early antigen IgG. If detecting the acuity antibodies simultaneously to two and more Herpesviridae family viruses, development of lung cancer is predicted.

EFFECT: method provides higher accuracy of prediction of development of the disease.

2 ex

FIELD: medicine.

SUBSTANCE: method of simultaneous immunochromatography analysis of PSA and CEA oncoantigens is offered. The analysis involves using a test strip which contains three segments A, B and C; the segment A overlaps 1-2 mm of the segment B. The segment A represents an inert porous carrier made of fibre glass ("ПЭД") with two reaction zones 1 and 2 applied on its surface. Mice monoclonal PSA and CEA antibodies conjugated with colloidal gold are respectively applied on zones 1 and 2. The conjugates are applied in the form of parallel strips in the centre of "ПЭД" perpendicularly to a fluid flow. The segment B represents nitrocellulose immobilised on a lavsan substrate with two test zones applied on its surface (monoclonal PSA and CEA antibodies in each), and a reference area (mice immunoglobulin antibodies).

EFFECT: test enables the simultaneous detection of the patients with the high blood serum PSA and CEA antigen contents in screening assays.

6 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: analysed sample is studied simultaneously by two methods: the first one is a indirect immunofluorescence (IIMF) reaction, while the second one involves a polymerase chain reaction (PCR); the IIMF provides using monoclonal antibodies "BCKK" (P-384D and 434D). The antibodies interact with the capsular antigen F1 specific for Y.pestis species, or the plasmid-temperature-independent surface protein PFV which is found in all Y.pestis strains and rare R-form Y.pseudotuberculosis strains. The bacteria luminescence shows the presence of native or fraction-less Y.pestis bacteria, or typical and PFV-atypical Y.pseudotuberculosis strains in the sample. The PCR is conducted by two pairs of primers vlm33for/ISrevl754 - specific for Y.pestis species, and JS - specific for Y. pseudotuberculosis species. The values derived with the first pair of the primers are estimated as positive if observing the amplicons in 400 bps, and with the second pair if observing the amplicons in 223 bps; the analysed sample is identified by the matching the IIMF and PCR values with the reference strains.

EFFECT: method provides quick identification and high-reliability differentiation of all strains.

7 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves evaluating proliferating processes by calculating index of positive cell nuclei (Ki-67). The Ki-67 value being from 6 to 16%, erosive ulcerating stomach lesions accompanied by stomach hemorrhage and hemorrhagic shock is to be predicted. The value being from 17 to 30%, erosive ulcerating stomach lesions without hemorrhage is to be predicted.

EFFECT: high accuracy of prognosis.

1 tbl

FIELD: medicine, virology.

SUBSTANCE: invention relates to diagnosis of infection caused by the Epstein-Barr virus. Method involves carrying out the indirect immune peroxidase reaction followed by histochemical staining and detection of the Epstein-Barr virus antigen. Additionally, method provides diagnosis of severity for the infectious mononucleosis course based on the expression of Epstein-Barr virus antigen. Invention provides enhancing precision in diagnosis of infection caused by the Epstein-Barr virus and assay for severity in course of the infectious mononucleosis.

EFFECT: improved diagnosis method.

1 tbl, 2 ex

FIELD: medicinal biochemistry.

SUBSTANCE: the present innovation deals with detecting oncoprotein E7 of human papilloma virus (HPV) in biopsy sample with the help of the pairs of monoclonal antibodies referring to IgG2a and IgG2b groups chosen out of the following groups: 716-321, 716-325, 716-332, 716-343, 716-281, 716-288 one of which is indicated for primary protein binding and another, being the antibody conjugate with enzymatic label - to detect the complexes developed.

EFFECT: higher sensitivity of the method.

5 cl, 4 dwg, 4 ex, 2 tbl

FIELD: medicine, therapy, obstetrics.

SUBSTANCE: at gestation terms of 20-28 wk in peripheral blood one should detect the index for the ratio of relative content of CD4+ to CD8+ lymphocytes. At values of CD4+/CD8+ being equal to or below 2.4 it is possible to predict positive effect of common therapy, and at values being above 2.4 one should predict thorough and prolonged therapy. The method enables to match another therapeutic tactics in due time.

EFFECT: higher accuracy of prediction.

3 ex, 1 tbl

FIELD: medicine, obstetrics.

SUBSTANCE: one should detect during pregnancy-free period relative content of CD38+ lymphocytes in peripheral blood, at its value being either equal to or above 12% one should predict efficient restoration of reproductive function. The method is very simple in application.

EFFECT: higher accuracy and sensitivity of detection.

3 ex, 1 tbl

FIELD: medicine, pediatrics.

SUBSTANCE: in 5-10-d-aged neonatals one should detect relative content of CD8+HLA-DR+ lymphocytes in peripheral blood and at its value being below 2.4% it is possible to predict the healing at different types of neonatal infections.

EFFECT: higher accuracy of prediction.

3 ex, 1 tbl

FIELD: medicine, gynecology.

SUBSTANCE: invention relates to a method for diagnosis of internal endometriosis in peripheral venous blood of women wherein the relative content of lymphocytes CD25+ is determined. Internal endometriosis is diagnosed at values of this index 6% or above. Proposed method provides carrying out diagnosis of internal endometriosis in women with high precision, sensitivity and specificity that allows carrying out the correct and well-timed necessary complex of curative-prophylactic treatment.

EFFECT: improved method for diagnosis.

1 tbl, 3 ex

FIELD: medicine, immunological laboratory diagnostics.

SUBSTANCE: at terms from 6 to 12 wk of gestation one should study relative content of CD3+CD16+ lymphocytes in peripheral venous blood and at its values being either equal or above 5.4% one should predict the development of light-degree gestosis to carry out the complex of curative-prophylactic means.

EFFECT: higher efficiency of prediction.

3 ex, 1 tbl

FIELD: medicine, laboratory diagnostics.

SUBSTANCE: during the 1st trimester of pregnancy (6-13 wk) in peripheral venous blood in women at risk of failed pregnancy one should detect relative content of CD16+CD56- lymphocytes and at its value being either equal or below 11% it is possible to predict the development of infectious diseases in full-term neonatals during the first 7-10 d of their lives. The innovation enables to predict the development of local form of infectious-inflammatory diseases in full-term neonatals.

EFFECT: higher accuracy of prediction.

3 ex, 1 tbl

FIELD: medicine, clinical laboratory diagnostics.

SUBSTANCE: in the sample of peripheral venous blood one should determine relative content of CD45RO+ lymphocytes and at its value being equal to 31% or lower it is possible to diagnose external genital endometriosis. The method is atraumatic and enables to diagnose external genital endometriosis at high accuracy.

EFFECT: higher efficiency of diagnostics.

3 ex, 1 tbl

Up!